Locknload,
You've mentioned some great investments there, if you got in at the right time. Can you honestly say that any of them have the potential to be worth ten times what they currently are by the end of this year. Do you concede that by the end of this year $7 is not out of the question for NWBO. I frankly believe even more than that is possible, but what if we only do half that, i.e. $3.50, can any of the investments you mention do 5 times their current price in the next half year, how about even in a year, would you expect any of them to do it in even 5 years.
I can't say that I know of any other stock with this sort of potential, but there are other stocks that no doubt will do it. Biotech's certainly have risks, but the rewards can be tremendous. In our case, we've been manipulated by the likes of AdamF and others to the point that I believe we're greatly underpriced. Where should we be, I believe at least at the $2 we were approaching before AdamF lied about Dr. Liau ducking the presentation because the vaccine failed on PFS. He didn't simply say the trial failed due to not meeting PFS, he alleged that Dr. Liau that Dr. Liau was lying about Covid as she didn't wish to admit DCVax-L was a failure.
Has anyone heard Dr. Liau, or any other Dr. involved in the trial called it a failure, I don't think so, but that doesn't matter, a guy with a Poly-Sci degree has said so, and he's spooked the market. Did the company call his bluff, yes and no, the presentation went on and clearly identified the OS benefits as scheduled at NYAS, they presented much the same data in a speech by Dr. Ashkan in their booth at ASCO, but no, they have maintained their quiet period so they've not directly taken on AdamF. No direct statement has come from them on the matter, or much else other than the simple fact that they continue to work toward approval. It's said that actions speak louder than words, our problem is not knowing all the actions NWBO has taken over nearly the last two years.
I can't say with absolute certainty what actions they've taken, but I believe we're far closer to approvals from all 4 regulators then we were when data locked. I believe we're much closer to the approval of the FlaskWorks unit then we were back then as well. Will one or more approval come this year, I certainly can't say so, but I still believe it's very possible.
I believe we'll learn a great deal more by the time we have the Annual Meeting, but I can't say when that will be. If investors wished to sue, they could force it before the company wants it, but if they did, and if the company was still under a quiet period legally, we wouldn't learn much.
I believe we should do it their way, even if that means waiting a few months longer. I don't fear that we've lost Merck or anyone else based on their partnerships with other companies, we're different and potential partners know it. If they wish to partner, or buyout NWBO by now they ought to realize it will be on terms that L.P. demands. Perhaps we could move faster with the support and billions a partnership would bring in, but with, or without it, she can take the vaccine to approval and the price will grow with each regulator that says yes and in time all 4 will say yes, and many others will say yes after they do.
Certainly no one will pay L.P.'s price today, they'd be hung for paying 30, 40, or perhaps 50 times the current price, they won't pay 10, or even 5 times the current price, but they may pay double the current price. If L.P.'s price is $20, once all is revealed don't you think that she can get the price to $10 if not this year, by a year from now, I certainly do. Can anyone deny that with any two of the regulators approving, and the others on the way, $10 is overpriced, I don't think so.
At $10 this would certainly be the best investment of my life, I believe that would be true for many here, but at $10 I believe we'd only be at the point where a partnership, or buyout could come at any time at $20 or more.
Gary
AI
